Imperial Innovations supports NanoBioDesign
Imperial Innovations, the technology commercialisation company of Imperial College London, has completed its first investment in a biotech company since its private placement in April 2005. The company has invested into Imperial spin-out, NanoBioDesign, an organisation developing a range of screening systems to speed up the drug discovery process.
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
NB Renaissance, Chequers to exit Biolchim to trade
US conglomerate J.M. Huber has agreed to buy the Italian specialty fertilizers producer
ArchiMed reaps 4x on Bomi sale to UPS
Deal is first full exit from specialist healthcare investor's maiden mid-market fund
GP Profile: Greenpeak Partners on emerging manager fundraising and specialisation
Buy-and-build specialist looks for portfolio add-ons as it contemplates hitting the road for a new fund in 2023
Summa opens North American office
Three existing partners will lead the California office, which is the GP’s first beyond Europe